Amplia Therapeutics Limited announced that Mr. Tim Luscombe will replace Mr. Hamish George as Chief Financial Officer (CFO) of the Company. Mr. Luscombe is a highly experienced Chartered Accountant who holds a Bachelor of Commerce from the University of Melbourne and a Certificate in Governance Practice from the Governance Institute of Australia. He is a Director at Bio101 Financial Advisory and has been working with Amplia in a senior accounting capacity over the last two years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.06 AUD | 0.00% | -3.23% | -25.00% |
Apr. 16 | Amplia Therapeutics to Raise AU$4.3 Million for Cancer Trials, Drug Capsule Manufacturing | MT |
Mar. 27 | Amplia Concludes Phase I Trials of Anti-Cancer Drug; Prepares for Phase II | MT |
1st Jan change | Capi. | |
---|---|---|
-25.00% | 7.69M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ATX Stock
- News Amplia Therapeutics Limited
- Amplia Therapeutics Limited Announces Chief Financial Officer Changes